Every 8-K that Lexaria Bioscience Corp. (LEXX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LEXX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LEXX filings page.
Lexaria Bioscience Corp. (LEXX) entered into definitive agreements for the immediate exercise of outstanding warrants to purchase 453,969 shares of common stock at a reduced exercise price of $12.92 per share, with closing expected on or about September 9, 2026, subject to customary conditions.
In return for cash exercise of these registered warrants, Lexaria will issue in a private placement new unregistered Series A and Series B warrants for up to 453,969 shares each, both exercisable immediately at $12.67 per share. Series A warrants will expire five years after the effective date of a resale registration statement, while Series B warrants will expire eighteen months after that date.
The transaction is expected to generate approximately $5.9 million in gross proceeds before fees, which, together with a recently received $2.6 million tax rebate from the Australian Tax Office, is expected to be used for working capital and to support operations and research and development programs in 2027. Lexaria highlights its DehydraTECH drug delivery platform and a portfolio of 66 granted patents worldwide.
Lexaria Bioscience Corp. (LEXX) disclosed that its wholly owned Australian subsidiary, Lexaria (AU) Pty Ltd, received an Australian R & D Tax Incentive Credit of AUD$3,666,611.98 on August 28, 2026. The credit relates to research and development costs for its Australian clinical study GLP-1-H24-4.
The funds have been deposited into the subsidiary’s Australian bank account and are intended to be used to pursue additional research and development opportunities in Australia. Lexaria (AU) holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products in Australia.
Lexaria Bioscience Corp. reported that on August 17, 2026 it received notice from Nasdaq that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As a result, the previously requested Nasdaq hearing has been cancelled, and the company’s common stock will continue to be listed and trade on The Nasdaq Capital Market. This removes an overhang related to potential delisting and clarifies that the company currently meets Nasdaq’s bid price standards.
Lexaria Bioscience Corp. reported receiving a Nasdaq Capital Market notification on August 4, 2026 that its common stock is subject to delisting for failing to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum $1.00 bid price within a 180-day compliance period. The company had already completed a reverse stock split on August 3, 2026, after which its shares have been trading on Nasdaq under CUSIP 52886N604 with a bid price currently above the $1.00 requirement. Lexaria has requested a hearing and paid the related fee, which stays any suspension or delisting while it seeks to demonstrate renewed compliance, and it states that it expects to regain full compliance and maintain continuous Nasdaq trading.
Lexaria Bioscience Corp. will implement a 1-for-15 reverse stock split of its common stock effective at 12:01 am EST on August 3, 2026, aiming to increase its share price and regain compliance with Nasdaq’s $1.00 minimum bid price requirement under the Minimum Price Rule.
The split will reduce issued shares from 24,787,446 to approximately 1,652,518 shares, with fractional shares rounded up, and will proportionally adjust all authorized shares, options, and warrants, including their exercise prices. Authorized shares will decrease from 220,000,000 to 14,666,667, while each shareholder’s percentage ownership remains unchanged.
Lexaria plans to request a Nasdaq hearing in connection with its 180-day compliance period and expects to meet the Minimum Price Rule in mid-August. Post-split, the stock will continue trading on Nasdaq under the symbol LEXX with a new CUSIP number 52886N604. The company also highlights its DehydraTECH drug delivery platform and a portfolio of 66 granted patents.
Lexaria Bioscience Corp. reported that on February 4, 2026 it received a Nasdaq notice that its common stock no longer meets the Nasdaq Capital Market’s minimum bid price requirement of $1.00 per share. The stock remains listed and continues to trade under the symbol LEXX.
The company has 180 calendar days, until August 3, 2026, for its closing bid price to be at or above $1.00 per share for at least 10 consecutive business days (and up to 20 at Nasdaq’s discretion) to regain compliance. If it does not do so, Lexaria may qualify for an additional 180‑day period if it meets all other initial listing standards and notifies Nasdaq of plans to cure the deficiency, potentially including a reverse stock split.
If Lexaria cannot meet these conditions, Nasdaq may move to delist the stock, and the company would then have the opportunity to appeal. Lexaria states that it intends to actively monitor its share price and evaluate options to address the deficiency, but it notes there is no assurance it will regain or maintain compliance.
Lexaria Bioscience Corp. reported the results of its annual shareholder meeting held on January 27, 2026. A total of 8,380,389 shares, or 37.71% of issued share capital as of December 1, 2025, were represented in person or by proxy.
Shareholders elected all seven director nominees, with approval levels ranging from 73.6% to 96.4%. They also approved the appointment of Malone Bailey LLP as auditors, with 97.0% of votes cast in favor.
In addition, shareholders voted to ratify the lawful actions of the directors for the past year, with 90.0% approval, signaling broad support for the company’s current leadership and governance decisions.
Lexaria Bioscience Corp. entered a securities purchase agreement with institutional investors and completed a combined registered direct offering and private placement, issuing 2,661,600 shares of common stock at $1.315 per share and 2,661,600 warrants with a $1.19 exercise price for gross proceeds of approximately $3.5 million before fees.
The shares were sold under an effective shelf registration, while the warrants and their underlying shares were issued in a private placement under Securities Act exemptions, with a 4.99% beneficial ownership cap that can be increased to up to 9.99% on notice. Lexaria agreed to file a resale registration statement for the warrant shares within specified deadlines, accepted a 30-day restriction on additional equity issuance and new registration filings (subject to exceptions), and plans to use net proceeds for working capital and other general corporate purposes. H.C. Wainwright & Co. acted as placement agent, earning a 7.0% cash fee, 93,156 warrants with a $1.6438 exercise price, and specified expense reimbursements.
Lexaria Bioscience Corp. entered into a securities purchase agreement with institutional investors, issuing 2,666,667 shares of common stock in a registered direct offering at $1.50 per share and, in a concurrent private placement, 2,666,667 warrants exercisable at $1.37 per share. The transaction, which closed on September 29, 2025, generated approximately $4.0 million in gross proceeds that the company plans to use for working capital and general corporate purposes.
The private placement warrants are immediately exercisable for five years from the effectiveness of a resale registration statement and include a beneficial ownership cap of 4.99%, which holders may increase up to 9.99% with notice. Lexaria agreed to file a resale registration statement for the warrant shares shortly after signing and to keep it effective until the investors no longer hold these securities.
H.C. Wainwright & Co. acted as placement agent, receiving a 7.0% cash fee on gross proceeds and 93,333 warrants with a $1.875 exercise price, plus specified expense reimbursements. The company also agreed to a 60-day restriction on most additional equity issuances and related registration filings, with limited exceptions.
Lexaria Bioscience Corp. terminated its Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC effective September 19, 2025. This agreement had allowed the company to issue and sell, from time to time, up to $5,000,000 of its common stock through or to JonesTrading as sales agent or principal.
By the time of termination, Lexaria had sold only 14,995 shares under the program, generating $38,236 in gross proceeds. With the agreement now ended, the company no longer has this specific at-the-market equity facility available for future common stock sales.